A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

Exclusion Criteria

• •1. Any clinically significant underlying illness in the opinion of the Investigator.
• •2. Poor venous access.
• •3. Prior exposure to ARN-75039.
• •4. History of drug or alcohol abuse within 1 year of Screening in the opinion of the investigator, or a positive test for drugs of abuse or alcohol at Screening or Day -1.
• •5. Use of any prescription or over-the-counter (OTC) medications, including food supplements, vitamins, herbal medications (e.g., St. John's wort), and cannabis, with the exception of contraceptive medications and as needed (prn) acetaminophen or paracetamol (not exceeding 2 grams/day) within 7 days prior to study drug administration and through the Day 15 Discharge visit.
• •6. Any female who is pregnant or breastfeeding, or any female who is planning to become pregnant during the study and safety follow-up period.
• •7. Currently enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) or plans to enroll in another investigational device or drug study during the course of this study.
• •8. Inability to ingest all capsules/tablets of a multi-capsule dose within 5 minutes of ingestion of the first capsule/tablet.
• •9. Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) at Screening; participants with adequately treated HCV are eligible for enrollment.
• •10. Consumption of Seville oranges, grapefruit or grapefruit juice within 72 hours prior to Day 1 or during the study.
• •11. History of malignancy, except adequately treated basal cell carcinoma or in situ carcinoma of the uterine cervix.
• •12. Smoking cigarettes, cigars, cigarillos or E-cigarettes
• •13. Any reason or condition that, in the investigator's opinion, may compromise study participation, present a safety risk to the participant, or may confound the interpretation of the study results.
• •14. A QT duration corrected for heart rate by Fridericia's formula (QTcF) \> 450 millisecond (msec) based on either single or averaged QTcF values of triplicate ECGs obtained over a 3-minute interval (at Screening).
• •15. Blood product (including plasma) donation within 30 days before Screening.
• •16. Unwilling to consume a breakfast on study drug administration days.
• •17. History of:
• •* Structural abnormality of the GI tract or a disease or history of a condition that can affect GI motility.
• •* Inflammatory bowel disease (even if treated and currently in remission).
• •* Diverticulitis or any other chronic condition such as chronic pancreatitis, polycystic kidney disease, ovarian cysts, endometriosis, lactose intolerance that can be associated with abdominal pain or discomfort and could confound the assessments in this trial.
• •* Chronic idiopathic diarrhea.
• •18. Formally diagnosed colonic inertia or conditions that can be associated with constipation: pseudo-obstruction, colonic inertia, megacolon, megarectum, bowel obstruction, descending perineum syndrome, solitary rectal ulcer syndrome, systemic sclerosis, lower tract evacuation disorders, functional outlet delay (e.g., rectal prolapse, anismus, etc.).
• •19. Current active peptic ulcer disease (i.e., disease that is not adequately treated or stable with therapy.)
• •20. Potential central nervous system cause of constipation (e.g., Parkinson's disease, spinal cord injury, and multiple sclerosis).
• •21. Participant currently has both unexplained and clinically significant alarm symptoms (lower GI bleeding \[rectal bleeding or heme-positive stool\], iron-deficiency anemia or any unexplained anemia, or weight loss) or systemic signs of infection or colitis.
• •22. History of chronic/generalized pruritus and/or skin rash of unknown origins.
• •23. Participants with diagnosed Type 1 or Type 2 diabetes, or with a fasting blood glucose value \> 125 mg/dL during the screening period.